Inhibikase Therapeutics, Inc.IKTNASDAQ
LOADING
|||
EPS Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-20.45%
↓ 22% below average
Average (30q)
-16.77%
Historical baseline
Range
High:73.85%
Low:-471.43%
Volatility
-3251.2%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | -20.45% |
| Q2 2025 | 26.67% |
| Q1 2025 | 11.76% |
| Q4 2024 | 73.85% |
| Q3 2024 | 1.52% |
| Q2 2024 | 9.59% |
| Q1 2024 | -7.35% |
| Q4 2023 | 20.93% |
| Q3 2023 | 22.52% |
| Q2 2023 | -27.59% |
| Q1 2023 | 12.12% |
| Q4 2022 | 7.39% |
| Q3 2022 | 2.82% |
| Q2 2022 | 0.00% |
| Q1 2022 | 8.33% |
| Q4 2021 | -12.15% |
| Q3 2021 | 17.05% |
| Q2 2021 | 17.83% |
| Q1 2021 | -80.46% |
| Q4 2020 | -77.55% |
| Q3 2020 | -58.06% |
| Q2 2020 | 22.50% |
| Q1 2020 | -25.00% |
| Q4 2019 | 64.04% |
| Q3 2019 | 48.26% |
| Q2 2019 | -35.43% |
| Q1 2019 | -71.62% |
| Q4 2018 | 0.00% |
| Q1 2018 | -471.43% |
| Q4 2017 | 0.00% |
| Q1 2017 | 0.00% |